Skip to main content

Advertisement

Table 2 Tumor targeting and normal organ distribution of i

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

  Time points (h)
Tissue 24 48 72 96 168
Blood 6.84 ± 2.30 2.28 ± 0.53 1.12 ± 0.27 0.32 ± 0.12 0.08 ± 0.02
Tumor 21.42 ± 7.67 21.12 ± 2.85 21.55 ± 6.2 16.55 ± 2.35 8.01 ± 3.65
Liver 8.01 ± 1.63 4.98 ± 0.98 4.66 ± 0.62 3.55 ± 0.62 3.38 ± 0.67
Spleen 5.43 ± 1.64 3.61 ± 0.87 3.96 ± 1.19 2.63 ± 1.12 2.09 ± 0.80
Kidneys 13.13 ± 2.34 8.27 ± 0.84 6.00 ± 1.57 5.22 ± 0.94 2.66 ± 0.46
Lung 4.40 ± 1.14 2.23 ± 0.39 1.79 ± 0.31 1.06 ± 0.21 0.8 ± 0.26
Heart 3.57 ± 1.11 2.06 ± 0.23 1.86 ± 0.30 1.20 ± 0.21 0.78 ± 0.12
Femur 2.41 ± 0.48 1.78 ± 0.41 1.67 ± 0.24 1.01 ± 0.24 0.75 ± 0.22
  1. Athymic mice bearing s.c. LS-174T xenografts were injected with 111In- CHX-A"-panitumumab F(ab')2 (approximately 7.5 μCi). At the indicated time points, the mice (n = 5) were sacrificed by exsanguination; the tumor, blood, and major normal organs were harvested, wet-weighed, and the radioactivity measured. The values represent the average percent injected dose per gram (%ID/g) of tissue along and the standard deviations.